Oric Pharmaceuticals ORIC
Oric Pharmaceuticals, Inc. · Nasdaq · Pharmaceutical Preparations
$9.30+3.33%close on Oct. 28, 2026 · volume 1.4M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 20, 2026 | Dominic Piscitelli Chief Financial Officer | Sold 10b5-1 plan | 14,000 | $13.53 | $189,391 |
| Oct. 1, 2026 | Richard A. Heyman director | Sold 10b5-1 plan | 3,500 | $12.91 | $45,199 |
| Oct. 1, 2026 | Richard A. Heyman director · indirect | Sold 10b5-1 plan | 3,200 | $12.91 | $41,325 |
| Sept. 28, 2026 | Dominic Piscitelli Chief Financial Officer | Sold 10b5-1 plan | 13,400 | $13.53 | $181,258 |
| Sept. 24, 2026 | Dominic Piscitelli Chief Financial Officer | Sold 10b5-1 plan | 600 | $13.50 $13.50-$13.51 | $8,102 |
| Aug. 26, 2026 | Dominic Piscitelli Chief Financial Officer | Sold 10b5-1 plan | 77,000 | $13.69 | $1.05 million |
| July 24, 2026 | Richard A. Heyman director | Sold 10b5-1 plan | 7,000 | $12.02 | $84,140 |
| July 24, 2026 | Richard A. Heyman director · indirect | Sold 10b5-1 plan | 6,100 | $12.02 | $73,322 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 10 →Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedORIC Pharmaceuticals Presents Enozertinib Phase 1b Data at ESMO 2026 Showing 84% Systemic ORR and Plans Phase 3 Redwood-1 Start in 1H 2027
Results of operations and financial condition · Financial statements and exhibits